MY177686A - Therapeutic agent for dyslipidemia - Google Patents

Therapeutic agent for dyslipidemia

Info

Publication number
MY177686A
MY177686A MYPI2015700727A MYPI2015700727A MY177686A MY 177686 A MY177686 A MY 177686A MY PI2015700727 A MYPI2015700727 A MY PI2015700727A MY PI2015700727 A MYPI2015700727 A MY PI2015700727A MY 177686 A MY177686 A MY 177686A
Authority
MY
Malaysia
Prior art keywords
dyslipidemia
prevention
treatment
therapeutic agent
formula
Prior art date
Application number
MYPI2015700727A
Other languages
English (en)
Inventor
Takizawa Toshiaki
Yoshinaka Yasunobu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MY177686A publication Critical patent/MY177686A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2015700727A 2012-09-27 2013-09-27 Therapeutic agent for dyslipidemia MY177686A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27

Publications (1)

Publication Number Publication Date
MY177686A true MY177686A (en) 2020-09-23

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015700727A MY177686A (en) 2012-09-27 2013-09-27 Therapeutic agent for dyslipidemia

Country Status (20)

Country Link
US (4) US9572798B2 (https=)
EP (1) EP2902025B1 (https=)
JP (1) JP6238460B2 (https=)
KR (1) KR102098032B1 (https=)
CN (1) CN104640544B (https=)
AU (1) AU2013321918B2 (https=)
BR (1) BR112015006305B1 (https=)
CA (1) CA2901650C (https=)
EA (1) EA024873B1 (https=)
ES (1) ES2752039T3 (https=)
IL (1) IL237981B (https=)
IN (1) IN2015DN02966A (https=)
MX (1) MX357446B (https=)
MY (1) MY177686A (https=)
PH (1) PH12015500471A1 (https=)
PL (1) PL2902025T3 (https=)
PT (1) PT2902025T (https=)
SG (1) SG11201501740XA (https=)
TW (1) TWI598098B (https=)
WO (1) WO2014050134A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
US11419854B2 (en) 2017-06-30 2022-08-23 Kowa Company, Ltd. Medicament containing pemafibrate
JP7007379B2 (ja) * 2017-06-30 2022-02-10 興和株式会社 医薬組成物
US11298340B2 (en) * 2017-06-30 2022-04-12 Kowa Company, Ltd. Pharmaceutical composition
US11759456B2 (en) 2017-06-30 2023-09-19 Kowa Company, Ltd. Pharmaceutical composition
WO2019004447A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
JP7402687B2 (ja) * 2017-06-30 2023-12-21 興和株式会社 医薬組成物
HRP20241476T1 (hr) * 2017-06-30 2025-01-03 Kowa Company, Ltd. Farmaceutski pripravak
WO2019004453A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬品
JP2021506907A (ja) * 2017-12-21 2021-02-22 興和株式会社 高トリグリセライド血症の治療方法
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
JP2020105174A (ja) * 2018-12-27 2020-07-09 興和株式会社 医薬組成物
TWI891619B (zh) * 2018-12-27 2025-08-01 日商興和股份有限公司 醫藥品
US20220096443A1 (en) * 2018-12-27 2022-03-31 Kowa Company, Ltd. Pharmaceutical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7205321B2 (en) 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
JPWO2005009942A1 (ja) 2003-07-28 2006-09-07 杏林製薬株式会社 光学活性置換フェニルプロピオン酸誘導体
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
JP2008513458A (ja) 2004-09-16 2008-05-01 メルク エンド カムパニー インコーポレーテッド 異常脂質血症及び他の脂質障害の治療用化合物
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
AU2013321918B2 (en) 2018-05-10
HK1206620A1 (zh) 2016-01-15
EA024873B1 (ru) 2016-10-31
PL2902025T3 (pl) 2020-03-31
JP6238460B2 (ja) 2017-11-29
MX357446B (es) 2018-07-10
WO2014050134A1 (ja) 2014-04-03
TW201417811A (zh) 2014-05-16
EP2902025A1 (en) 2015-08-05
BR112015006305B1 (pt) 2020-11-17
CA2901650C (en) 2021-05-04
AU2013321918A1 (en) 2015-04-23
US20170112811A1 (en) 2017-04-27
EP2902025B1 (en) 2019-08-07
IL237981A0 (en) 2015-05-31
US11013722B2 (en) 2021-05-25
CN104640544B (zh) 2017-05-03
PT2902025T (pt) 2019-11-04
KR102098032B1 (ko) 2020-04-07
US20150196538A1 (en) 2015-07-16
EA201590653A1 (ru) 2015-07-30
CA2901650A1 (en) 2014-04-03
PH12015500471B1 (en) 2015-04-20
EP2902025A4 (en) 2016-03-02
TWI598098B (zh) 2017-09-11
PH12015500471A1 (en) 2015-04-20
MX2015003705A (es) 2015-06-10
SG11201501740XA (en) 2015-04-29
US20180185337A1 (en) 2018-07-05
IN2015DN02966A (https=) 2015-09-18
CN104640544A (zh) 2015-05-20
BR112015006305A2 (pt) 2017-07-04
US20190167645A1 (en) 2019-06-06
IL237981B (en) 2020-05-31
US9572798B2 (en) 2017-02-21
JPWO2014050134A1 (ja) 2016-08-22
US9931321B2 (en) 2018-04-03
KR20150063035A (ko) 2015-06-08
US10258609B2 (en) 2019-04-16
ES2752039T3 (es) 2020-04-02

Similar Documents

Publication Publication Date Title
PH12015500471A1 (en) Therapeutic agent for dyslipidemia
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12016502581A1 (en) TrK-INHIBITING COMPOUND
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
EA201690283A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
EP4663636A3 (en) Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
WO2013040227A3 (en) Therapeutic compounds
IN2014DN06869A (https=)
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
HK1217092A1 (zh) 治疗性化合物及其用途
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
EA201591175A1 (ru) Трициклические соединения в качестве ингибиторов cftr
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
EA201390619A1 (ru) 3-замещенные 6-(пиридинилметокси)пирролопиридиновые соединения
LV14468A (lv) Pretiekaisuma līdzeklis
TH153741A (th) 4-เฟนิล-ไพริดีนที่ได้รับการแทนที่สำหรับการบำบัดของโรคที่เกี่ยวข้องกับตัวรับ nk-1
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز